British pharma giant GlaxoSmithKline PLC (GSK) is expected to start from next month the global transfer of its oncology employees to Swiss peer Novartis AG under an asset swap deal sealed last year. Under the currently envisaged two-stage transfer plan,…
To read the full story
Related Article
- GSK to Transfer 3 Oncology Products to Novartis in Japan in November
October 26, 2015
BUSINESS
- Takeda Hands CEO Baton to Kim after 12-Year Weber Era
June 25, 2026
- EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
June 25, 2026
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…





